Antti Vuolanto, COO (DSc) is a biotech leader with vast experience within immuno-oncology, in-vitro diagnostics and bioinformatics. He co-founded Oncos Therapeutics where as a COO he was responsible for the clinical development program of an oncolytic adenovirus. Later, he had the responsibility of merging Oncos Therapeutics with the Norwegian immuno-oncology company Targovax. He served at Targovax as an Executive Vice President before joining Valo Therapeutics. Previously he has also held senior management positions at other biotech companies. Antti has studied biochemistry and bioprocess technology at Aalto University, Finland. He graduated as a doctor of science in technology in 2004. Antti Vuolanto, COO (DSc) is a biotech leader with vast experience within immuno-oncology, in-vitro diagnostics and bioinformatics. He co-founded Oncos Therapeutics where as a COO he was responsible for the clinical development program of an oncolytic adenovirus. Later, he had the responsibility of merging Oncos Therapeutics with the Norwegian immuno-oncology company Targovax. He served at Targovax as an Executive Vice President before joining Valo Therapeutics. Previously he has also held senior management positions at other biotech companies. Antti has studied biochemistry and bioprocess technology at Aalto University, Finland. He graduated as a doctor of science in technology in 2004.

immuno-oncology